Oman has licensed the world's first oral medication for Multiple Sclerosis (MS), a move which medical experts say will improve medication tolerability and compliance for many of Oman's 200 MS sufferers.
The Oman Ministry of Health has approved the Novartis-made drug Gilenya (fingolimod) for use in the relapsing remitting form of MS that affects around two-thirds of those diagnosed with the disease, which causes muscle weakness, problems with coordination and impaired concentration.
Making the new oral tablets available will remove the need for patients to undergo regular injections, allowing patients to enjoy a less restricted way of life and improving medication acceptance and compliance for those who cannot tolerate injections, said a leading Oman-based doctor who specialises in MS. Improved medication acceptance and compliance will optimize patient outcomes.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309